Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

ABSTRACT:

Background

Galectin-3 is a soluble ß-galactoside-binding lectin released by activated cardiac macrophages. Elevated levels of galectin-3 have been found to be associated with adverse outcomes in patients with heart failure. We evaluated the association between galectin-3 and long-term clinical outcomes in ambulatory heart failure patients enrolled in the HF-ACTION study.

Methods and results

HF-ACTION was a randomized, controlled trial of exercise training in patients with chronic heart failure caused by left ventricular systolic dysfunction. Galectin-3 was assessed at baseline in a cohort of 895 HF-ACTION subjects with stored plasma samples available. The association between galectin-3 and clinical outcomes was assessed using a series of Cox proportional hazards models. High

SUBMITTER: Felker GM 

PROVIDER: S-EPMC3261343 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature